Kathleen I. Pritchard: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m →‎Selected publications: added doi and url links
→‎Selected publications: added doi and url links
Line 39: Line 39:
*{{cite journal |date=July 1998|title=Is tamoxifen effective in prevention of breast cancer? |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)85002-2/fulltext |journal=[[The Lancet]] |publisher=Elsevier |volume=352 |issue=9122 |pages=80–81 |doi=10.1016/S0140-6736(98)85002-2}}
*{{cite journal |date=July 1998|title=Is tamoxifen effective in prevention of breast cancer? |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)85002-2/fulltext |journal=[[The Lancet]] |publisher=Elsevier |volume=352 |issue=9122 |pages=80–81 |doi=10.1016/S0140-6736(98)85002-2}}
*{{cite journal |date=June 2000|title=Current and future directions in medical therapy for breast carcinoma|url=http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20000615)88:12%2B%3C3065::AID-CNCR25%3E3.0.CO;2-P/pdf |journal=Cancer |publisher=Wiley |volume=88 |issue=S12 |pages=3065&ndash;3072 |doi=10.1002/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P}}
*{{cite journal |date=June 2000|title=Current and future directions in medical therapy for breast carcinoma|url=http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20000615)88:12%2B%3C3065::AID-CNCR25%3E3.0.CO;2-P/pdf |journal=Cancer |publisher=Wiley |volume=88 |issue=S12 |pages=3065&ndash;3072 |doi=10.1002/1097-0142(20000615)88:12+<3065::AID-CNCR25>3.0.CO;2-P}}
*{{cite journal |date=2003|title=Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data|url=http://clincancerres.aacrjournals.org/content/9/1/460s.full |journal=Clinical Cancer Research|publisher=American Association for Cancer Research |volume=9|issue=1|page=460S}}
*{{cite journal |date=2003|title=Endocrine Therapy of Advanced Disease: Analysis and Implications of the Existing Data|url=http://clincancerres.aacrjournals.org/content/9/1/460s.full |journal=[[Clinical Cancer Research]] |publisher=American Association for Cancer Research |volume=9|issue=1|page=460S}}
*{{cite journal |date=December 2005|title=Adjuvant endocrine therapies for pre-/perimenopausal women|url=http://www.thebreastonline.com/article/S0960-9776(05)80024-4/abstract |journal=[[The Breast (journal)|The Breast]] |publisher=Elsevier |volume=14|issue=6|pages=547&ndash;554 |doi=10.1016/S0960-9776(05)80024-4}}
*{{cite journal |date=December 2005|title=Adjuvant endocrine therapies for pre-/perimenopausal women|url=http://www.thebreastonline.com/article/S0960-9776(05)80024-4/abstract |journal=[[The Breast (journal)|The Breast]] |publisher=Elsevier |volume=14|issue=6|pages=547&ndash;554 |doi=10.1016/S0960-9776(05)80024-4}}
*{{cite journal |date=July 2007|title=Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life |url=http://www.ejcancer.com/article/S0959-8049(07)00440-6/abstract |journal=[[European Journal of Cancer]]|publisher=Elsevier |volume=43|issue=11|pages=1644&ndash;1645 |doi=10.1016/j.ejca.2007.05.027}}
*{{cite journal |date=July 2007|title=Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life |url=http://www.ejcancer.com/article/S0959-8049(07)00440-6/abstract |journal=[[European Journal of Cancer]]|publisher=Elsevier |volume=43|issue=11|pages=1644&ndash;1645 |doi=10.1016/j.ejca.2007.05.027}}
*{{cite journal |date=June 2008|title=Antihormone Therapy in Recurrent Metastatic Breast Cancer|url= |journal=JAMA|publisher=|volume=299|issue=23|page=2745}}
*{{cite journal |date=June 2008|title=Antihormone Therapy in Recurrent Metastatic Breast Cancer|url=http://jama.jamanetwork.com/article.aspx?articleid=182084 |journal=[[JAMA (journal)|JAMA: The Journal of the American Medical Association]] |publisher=|volume=299|issue=23|page=2745 |doi=10.1001/jama.299.23.2745-a}}
*{{cite journal |date=December 2010|title=Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?|url= |journal=Breast Cancer Research|publisher=|volume=12|issue=4|pages=1&ndash;2}}
*{{cite journal |date=December 2010|title=Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer? |url=http://www.breast-cancer-research.com/content/12/S4/S18 |journal=[[Breast Cancer Research]] |publisher=Springer |volume=12|issue=4|pages=1&ndash;2 |doi=10.1186/bcr2747}}


== References ==
== References ==

Revision as of 17:38, 19 November 2015

Kathleen I. Pritchard
NationalityCanadian
Alma materQueen's University
Occupation(s)Medical oncologist
Clinical trials research scientist
AwardsO. Harold Warwick Prize

Kathleen I. Pritchard is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada,[1] specializing in breast cancer therapies, and leading the clinical trials division of the centre.[2] She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology.[3] According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014[3][4] and 2015.[5]

Biography

Kathleen I. Pritchard grew up in Deep River, Ontario.[6] She graduated from the local high school in 1964.[6] She earned her Bachelor's in Science in 1968 from Queen's University in Kingston, Ontario and attained her medical degree there in 1971. Her Practicum in Internal Medicine was completed at Wellesley Hospital, Toronto Western Hospital, and Toronto General Hospital. Between 1973 and 1974 at the University of Toronto, Pritchard focused on research into melanoma and tumor immunology, and then in 1977 began researching breast cancer in clinical trials as a Research Fellow at the University of Toronto.[7]

Between 1978 and 1984, Pritchard conducted clinical trials at Women's College Hospital under an award granted by the National Cancer Institute of Canada (NCIC). In 1984, she was was appointed head of Medical Oncology and Haematology at Women's College Hospital and Chair of the Breast Cancer Site Group of the NCIC. Three years later, Pritchard moved to the Sunnybrook Regional Cancer Centre in Toronto[7] where she has served as head of Medical Oncology.[1] A decade later, in 1997, she was appointed to head the Clinical Trials and Epidemiology at the Odette Cancer Centre of Sunnybrook. She has been involved in numerous studies and is one of Canada's most-known academic physicians,[7] researching such topics as chemotherapy verses hormone therapy,[8] the effects of aging and menopause for risk of breast cancer,[9] and drugs which aid in non-recurrence.[10]

Memberships

Pritchard was one of the founders of the Canadian Oncology Society in 1978 and a founding member of the Canadian Association of Medical Oncology in 1988, serving as its president from 1990 to 1992. She served as Chair and Co-Chair of the Ontario Practice Guidelines Initiative's Breast Cancer Site Group between 1990 and 2002. She was elected to serve on the the Board of Directors for the American Society of Clinical Oncology in 2006.[7]

Awards and honors

In 2005, Pritchard was awarded the O. Harold Warwick Prize by the Canadian Cancer Society for her clinical trials work on breast cancer.[11] In 2015, she was the Scientific Honoree at the 14th Women of Action awards luncheon hosted by the Israel Cancer Research Fund in Toronto.[12]

Selected publications

References

  1. ^ a b Habib, Marlene (4 April 1997). "New Drug Offers Patients Hope". Brandon Sun. Brandon, Manitoba, Canada. p. 11. Retrieved 2 November 2015 – via Newspaperarchive.com. Open access icon
  2. ^ "New drug provides alternative for post-menopausal patients". Lethbridge Herald. Lethbridge, Alberta, Canada. 27 June 2000. p. 10. Retrieved 2 November 2015 – via Newspaperarchive.com. Open access icon
  3. ^ a b Mahendraraja, Shujanaa (23 July 2014). "Thomson Reuters ranked the top scientific researchers of the world: Meet the 19 U of T scholars on the list". University of Toronto. Retrieved 8 November 2015.
  4. ^ "The World's Most Influential Scientific Minds 2014" (PDF). Thomson Reuters. 2014. p. 31. Retrieved 8 November 2015.
  5. ^ "Highly Cited Researchers 2015". Thomson Reuters. 2015. Retrieved 2 November 2015.
  6. ^ a b Bitti, Mary Teresa (24 September 2009). "A training ground for biotech leaders". canada.com. Retrieved 8 November 2015.
  7. ^ a b c d "Kathleen Pritchard". Toronto, Canada: Ontario Institute for Cancer Research. 7 July 2009. Retrieved 2 November 2015.
  8. ^ "Fears of chemotherapy worse than breast cancer diagnosis". Lethbridge Herald. Lethbridge, Alberta, Canada. 19 May 1999. p. 7. Retrieved 2 November 2015 – via Newspaperarchive.com. Open access icon
  9. ^ "Hormone replacement carries risk". Medicine Hat Daily News. Medicine Hat, Alberta, Canada. 31 January 2000. p. 13. Retrieved 2 November 2015 – via Newspaperarchive.com. Open access icon
  10. ^ "Drug helps prevent recurrence of breast cancer". Lethbridge Herald. Lethbridge, Alberta, Canada. 15 July 2004. p. 6. Retrieved 2 November 2015 – via Newspaperarchive.com. Open access icon
  11. ^ "Research Awards: O. Harold Warwick Prize". Canadian Cancer Society. 2015. Retrieved 8 November 2015.
  12. ^ "Women of Action". Israel Cancer Research Fund. 2015. Retrieved 8 November 2015.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Kathleen_I._Pritchard&oldid=691412024"